Chen Jie, Pan Yuqin, He Bangshun, Ying Houqun, Sun Huiling, Deng Qiwen, Liu Xian, Wang Shukui
Department of Life Sciences, Nanjing Normal University; Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
J Cancer Res Ther. 2018;14(Supplement):S85-S89. doi: 10.4103/0973-1482.160917.
Recently, increasing studies investigated the association between inflammation parameter such as neutrophil to lymphocyte ratio (NLR) and the prognosis of cancers. However, the clinical and prognostic significance of NLR in breast cancer remains controversial.
This meta-analysis was conducted to establish the overall accuracy of the NLR test in the diagnosis of breast cancer.
A comprehensive search of the literature was conducted using PubMed and Web of Science. Six studies dating up to July 2014 with 2267 patients were enrolled in the present study. STATA 11.0 software (STATA Corporation, College Station, TX, USA) was selected for data analysis. In order to evaluate the association between NLR and overall survival (OS), disease-free survival (DFS), recurrence-free survival or cancer-specific survival, the hazard ratios (HRs), and their 95% confidence intervals (CIs) were extracted.
Subgroup analyses showed that NLR was a strong prognostic factor for OS in multivariate analysis (HR = 2.81, 95% CI = 2.13-3.71, P = 0.992) and without metastasis (HR = 1.45, 95% CI = 0.37-5.66, P < 0.001). Elevated NLR was associated with a high risk for DFS in subgroups of multivariate analysis (HR = 2.16, 95% CI = 1.67-2.80, P = 0.977) and mixed metastasis (HR = 2.13, 95% CI = 1.38-3.30, P = 0.84).
In summary, NLR may be considered as a predictive factor for patients with breast cancer.
最近，越来越多的研究调查了诸如中性粒细胞与淋巴细胞比值（NLR）等炎症参数与癌症预后之间的关联。然而，NLR在乳腺癌中的临床和预后意义仍存在争议。
本荟萃分析旨在确定NLR检测在乳腺癌诊断中的总体准确性。
使用PubMed和Web of Science对文献进行全面检索。本研究纳入了截至2014年7月的6项研究，共2267例患者。选择STATA 11.0软件（美国德克萨斯州大学站市STATA公司）进行数据分析。为了评估NLR与总生存期（OS）、无病生存期（DFS）、无复发生存期或癌症特异性生存期之间的关联，提取了风险比（HR）及其95%置信区间（CI）。
亚组分析显示，在多变量分析中，NLR是OS的一个强有力的预后因素（HR = 2.81，95%CI = 2.13 - 3.71，P = 0.992），且在无转移患者中也是如此（HR = 1.45，95%CI = 0.37 - 5.66，P < 0.001）。在多变量分析亚组（HR = 2.16，95%CI = 1.67 - 2.80，P = 0.977）和混合转移亚组（HR = 2.13，95%CI = 1.38 - 3.30，P = 0.84）中，NLR升高与DFS高风险相关。
总之，NLR可被视为乳腺癌患者的一个预测因素。
